Suggested remit: To appraise the clinical and cost effectiveness of secukinumab within its marketing authorisation for treating enthesitis-related arthritis or juvenile psoriatic arthritis.
Please note that following on from information provided to NICE by the company in March 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 3738
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 February 2026 | Discontinued. Please note that following on from information provided to NICE by the company in March 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 01 March 2023 | Suspended. This topic is currently suspended whilst conversations between the company, NICE & NHS England are ongoing. A further update will be available in due course. |
| 31 July 2020 - 28 August 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual